Challenging Clinicopathologic Scenarios: Traps to Avoid
Histopathology can be rendered useless without good clinical information, according to Dr. Olayemi Sokumbi, a dermatologist and dermatopathologist with Mayo Clinic. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Sokumbi about traps to avoid in challenging clinicopathologic scenarios. Learn how not to miss a diagnosis of dermatomyosit …
Histopathology can be rendered useless without good clinical information, according to Dr. Olayemi Sokumbi, a dermatologist and dermatopathologist with Mayo Clinic. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Sokumbi about traps to avoid in challenging clinicopathologic scenarios. Learn how not to miss a diagnosis of dermatomyosit … Continue reading "Challenging Clinicopathologic Scenarios: Traps to Avoid"
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl … 
A 44-year-old man with a history of diabetes, hypertension, and major depressive disorder presents to the office with the eruption shown for several months. The lesions are also all across the patient's back and have not resolved with twice-daily clobetasol 0.05% ointment application for 2 months. Which of the following is the most appropriate treatment?
A. Intralesional triamcinolone
B. Nar … 